TheEdgeResearch
Home / Stocks / MDCLF

MedinCell S.A. (MDCLF)

OTC Healthcare Biotechnology
$30.26 ▲ +0.00%
Market Cap
$1.09B
Sector
Healthcare
Industry
Biotechnology
Beta
1.00
52-Wk Range
6.9757-34.39
CEO
Christophe Douat
Country
FR
Currency
USD

MedinCell S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Jacou, OC, FR. The stock last traded at $30.26, up 0.00% on the session, giving a market capitalisation of $1.09B. On trailing twelve-month figures it carries a trailing P/E of -29.34, a net margin of -160.3%. Its beta of 1.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-29.34
Price / Sales
49.20
Price / Book
312.87
EV / EBITDA
-31.55
Gross margin
51.9%
Operating margin
-130.6%
Net margin
-160.3%
Return on equity
—
Debt / equity
18.74
Current ratio
4.67
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
150
IPO date
2021-01-05
Headquarters
Jacou, OC, FR
About MedinCell S.A.

MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.

More research on MDCLF
MDCLF technical analysis MDCLF TheEdge Score Compare against peers
Open full interactive analysis & DCF →